Abstract
Background: Evaluation of the feasibility for osteopontin (OPN) to serve as a biomarker in the prognosis and clinical-pathological features of prostate cancer (PCA) patients.Methods: The original publications related to OPN and PCA were comprehensively searched in the online databases, including PubMed, Embase, Cochrane Library, Web of Science, Medline, Wanfang and China National Knowledge Infrastructure up to August 2019. Results were analyzed by Revman 5.3 and Stata 12.0.Results: A total of 21 studies were included in the analysis and the result showed that the positive OPN expression group had a lower overall survival than the negative expression group (univariate: hazards ratio (HR) = 2.32, 95% confidence interval (95% CI) [1.74, 3.10], multivariate: HR = 2.41, 95% CI [1.63, 3.57]) and a lower biochemical relapse-free survival than the negative group (univariate: HR = 1.42, 95% CI [0.92, 2.17], multivariate: HR = 1.61, 95% CI [1.39, 1.87]). In addition, there was a higher expression level of OPN in PCA tissues than in normal prostate tissues (OR = 46.55, 95% CI [12.85, 168.59], P<0.00001) and benign prostatic hyperplasia (BPH) tissues (OR = 11.07, 95% CI [3.43, 35.75], P<0.0001). Moreover, OPN positive expression was also related to high Gleason score (OR = 2.64, 95% CI [1.49, 4.70], P=0.0009), high TNM stage (OR = 3.15, 95% CI [1.60, 6.20, P=0.0009), high Whitmore–Jewett stage (OR = 2.53, 95% CI [1.06, 6.03], P=0.04), high lymph node (OR = 3.69, 95% CI [1.88, 7.23], P=0.0001), and distant metastasis (OR = 8.10, 95% CI [2.94, 22.35], P=0.01). There was no difference observed in the differentiation of PCA (OR = 1.79, 95% CI [0.39, 8.33], P=0.46).Conclusion: OPN could be recognized as a promising diagnostic and prognostic biomarker for PCA patients.
Highlights
Prostate cancer (PCA) is the second most common malignancy in males, with an increasing risk in aged population [1,2]
The rest of studies were carefully examined on Title, Abstract, and Keywords, and 357 were excluded because they did not match the subject of this meta-analysis
We investigated the expression of OPN with the survival analyses in PCA patients and all the results showed that the high expression of OPN could decrease the survival time
Summary
Prostate cancer (PCA) is the second most common malignancy in males, with an increasing risk in aged population [1,2]. Current major clinical diagnostic methods for PCA include prostate-specific antigen (PSA) level test, trans-anal prostate ultrasound, prostate magnetic resonance, and needle biopsy [3,4,5,6,7]. The elevation of PSA is usually recognized as an indicator of PCA in clinical diagnosis, sometimes its production can be induced by benign prostatic hyperplasia (BPH) or inflammation. The expression of PSA does not increase in some highly differentiated PCA cases [8]. It will be critical to discover novel secretory biomarkers, which are directly associated with the clinical pathological features of PCA, to enable its convenient diagnosis and prognosis. Evaluation of the feasibility for osteopontin (OPN) to serve as a biomarker in the prognosis and clinical-pathological features of prostate cancer (PCA) patients. Conclusion: OPN could be recognized as a promising diagnostic and prognostic biomarker for PCA patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
